Artelo Biosciences, Inc. (ARTL) Stock

Artelo Biosciences, Inc. (ARTL) is a Healthcare stock trading at $0.69 (as of 2026-08-21), with a market capitalization of $3.18M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company developing therapies intended to modulate the endocannabinoid system. Its pipeline includes ART27.13 (for cancer-related anorexia), ART12.11 (for inflammatory bowel disease and PTSD), and ART26.12 (for prostate and breast cancer and PTSD).

Valuation — source: SEC EDGAR (first-party)
Price$0.69
Market Cap$3.18M
Price / Book0.64
Profitability & Growth — source: SEC EDGAR
Return on Equity-253.6%
Current Ratio3.00
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderAltshuler Shaham Ltd ($484194.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOGregory D. Gorgas
Employees6
CountryUS
IPO Date2019-06-21

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Revelation Biosciences, Inc. (REVB)
  • FibroBiologics, Inc. Common Stock (FBLG)
  • GRI Bio, Inc. (GRI)
  • Genprex, Inc. (GNPX)
  • 60 Degrees Pharmaceuticals, Inc. (SXTP)
  • Ernexa Therapeutics Inc. (ERNA)
  • Onconetix, Inc. (ONCO)
  • HCW Biologics Inc. (HCWB)
ARTL earnings history · ARTL institutional & insider holders · ARTL KPIs & operating metrics · ARTL financials · ARTL investor presentations & press releases · ARTL SEC filings · ARTL peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.